Three Reasons to Join the Industry-Wide Effort to Speed Time-to-Therapy for Specialty Pharmacy

Today’s guest post comes from Lee Ann Stember, President and CEO of the National Council for Prescription Drug Programs (NCPDP). Lee Ann discusses the crucial importance of getting patients timely access to specialty therapies. She invites Drug Channels readers to participate in NCPDP’s specialty pharmacy work group and its four task groups. Your participation will help establish and refine standards that will benefit patients and all industry participants. It’s simple. Create an account at www.dms.ncpdp.org and then select your preferred task groups. You can also click here to register for upcoming NCPDP meetings. Read on for Lee Ann’s insights and to get more … Continue reading Three Reasons to Join the Industry-Wide Effort to Speed Time-to-Therapy for Specialty Pharmacy

Delivering Care Beyond Prescriptions: A Marketplace Opportunity for Independent Pharmacies

Today’s guest post comes from Brian Nightengale, President, Good Neighbor Pharmacy at AmerisourceBergen. Brian discusses the challenges facing independent pharmacies. He outlines an intriguing growth vision for pharmacies that provide medication therapy management and other patient care services. For more on how pharmacies can enhance care and lower medical expenses, see Delivering Care Beyond Prescriptions: A Marketplace Opportunity for Independent Pharmacies. Read on for Brian’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only.          Powered by … Continue reading Delivering Care Beyond Prescriptions: A Marketplace Opportunity for Independent Pharmacies

The NDC Shortage: What the FDA Could (and Should) Do to Address It

Today’s guest post comes from Patricia Milazzo, Senior Director, Embedded Content with Clinical Effectiveness at Wolters Kluwer, Health. As Patty explains, the U.S. Food & Drug Administration (FDA) will run out of 5-digit National Drug Code (NDC) codes within the next ten to fifteen years. She describes how the FDA can minimize the negative effects of the inevitable change in NDC format. To learn more about the debates and best practice recommendations, download the complete paper, The NDC Shortage: What the FDA Could (and Should) Do to Address It. Read on for Patty’s insights. Read more » Copyright © 2006-2018 … Continue reading The NDC Shortage: What the FDA Could (and Should) Do to Address It

Commercializing Cell and Gene Therapies with High-Touch Services

Today’s guest post comes from Layne Martin, VP/GM, Specialty Distribution and Third-Party Logistics at McKesson Life Sciences. Companies commercializing cell and gene therapies face many novel challenges, including: supply chain logistics, patient access, adherence, outcomes collection, and data analysis. Layne reviews the crucial issues and explains the services needed for success. McKesson Life Sciences has developed a portfolio of patient-centric solutions to help cell and gene therapy companies. To learn more, download their new white paper: The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs. Read on for Layne’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. … Continue reading Commercializing Cell and Gene Therapies with High-Touch Services

Enhancing Care For and Management of Hepatitis C Patients

Today’s guest post comes from Lily Duong, Chief Clinical Officer at Therigy. Lily discusses challenges treating Hepatitis C patients and explains how a specialty patient management platform can improve outcomes. She introduces Therigy’s latest publication series: Specialty Pharmacy Standards of Care. Download the first volume in this series here: Specialty Pharmacy Standards of Care: Hepatitis C. Read on for Lily’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only.          Powered by WPeMatico Continue reading Enhancing Care For and Management of Hepatitis C Patients

McKesson: Biopharma Companies Need an Integrated, Customized and High-Touch Approach to Solve Critical Commercialization Challenges

Today’s guest post comes from Shawn Seamans, President of McKesson Life Sciences. Shawn discusses the channel and commercialization complexities associated with launching and managing specialty medications. He then outlines McKesson Life Sciences, a business that brings together McKesson’s multiple solutions for connecting biopharma companies, providers, pharmacies and payers. These solutions also help patients access their therapies. To learn more, visit McKesson Life Sciences or email LifeSciences@mckesson.com. Read on for Shawn’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use … Continue reading McKesson: Biopharma Companies Need an Integrated, Customized and High-Touch Approach to Solve Critical Commercialization Challenges

DIR Fees: A Prescription While You Wait

Today’s guest post is sponsored by Elsevier and written by Todd Grover, Co-Founder, Glass Box Analytics and President, PharmacyFocus. Todd discusses some of the challenges associated with Direct and Indirect Remuneration (DIR) fees. He explains how Elsevier’s Predictive Acquisition Cost (PAC) pricing tool helps pharmacies better manage DIR fees and challenge insufficient reimbursements. Learn more by downloading Elsevier’s infographic: Managing the Impact of DIR Fees. Read on for Todd’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only. … Continue reading DIR Fees: A Prescription While You Wait

It’s Time to Rethink Channel Strategy for Oral Oncolytics

Today’s guest post comes from Akin Odutola, Senior Vice President, Specialty and Branded Product Access, Strategic Global Sourcing, at AmerisourceBergen. Akin discusses the challenges facing patients treated with oral oncology drugs in community practices and health systems. He then describes AmerisourceBergen’s solution for coordinating patient care and providing aggregated specialty pharmacy data from healthcare providers. To learn more, download Rethink: Channel Strategy for Oral Oncolytics. Read on for Akin’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use … Continue reading It’s Time to Rethink Channel Strategy for Oral Oncolytics

Artificial Intelligence (AI): How Specialty Pharmacies Are Making Medication Package Management More Predictable, Scalable, and Efficient

Today’s guest post comes from Scott Knight, Founder and President at ParcelShield. Scott explains how artificial intelligence is being used to improve medication package management in specialty pharmacy. It’s an intriguing look at the application of next-generation technologies that can benefit patients. To learn more about AI in specialty pharmacy, download ParcelShield’s free white paper Man Vs. Machine: How Artificial Intelligence (AI) Makes Specialty Parcel Management More Predictable, Scalable, and Efficient. Read on for Scott’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This … Continue reading Artificial Intelligence (AI): How Specialty Pharmacies Are Making Medication Package Management More Predictable, Scalable, and Efficient

Redefining Digital Health: How a Different Approach Can Get Manufacturers Closer to Patients

Today’s guest post comes from Mary Roberts, Vice President of Business Development at EnvoyHealth, a subsidiary of Diplomat. Mary describes the next generation of patient services and explains how manufacturers can use new digital health tools to get closer to patients. Visit envoyhealth.diplomat.is/innovative to learn more about using technology to enhance patient services and differentiate brands. Read on for Mary’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only.          Powered by WPeMatico Continue reading Redefining Digital Health: How a Different Approach Can Get Manufacturers Closer to Patients